Optimization of treatment of irritable bowel syndrome in children

O.B. Hanzii, L.G. Voloshyna, O.M. Вabadzhanian, N.V. Pavlenko, O.V. Drachevska


Background. Factors that trigger several pathophysiological mechanisms may simultaneously be involved in the occurrence of irritable bowel syndrome (IBS). Disorders of the intestinal microbiota play a significant role in the pathogenesis of the disease in children, given the characteristics of the child’s body. Changes in the composition of the intestinal microflora may be accompanied by movement disorders and impaired sensory sensitivity of the intestines, which form the basis for the formation of pain, dyspeptic manifestations and stool disorders. The lack of effect from the treatment of IBS may be due to the presence of violations of the intestinal biocenosis in the child; therefore, in accordance with the recommendations of the Rome IV criteria, it is necessary to correct the intestinal microflora. The purpose is to study the effectiveness of synbiotic Optilact® in the treatment of irritable bowel syndrome in children. Materials and methods. Thirty-three children aged 8 to 14 years with irritable bowel syndrome (variant with constipation) were examined. The diagnosis was made on the basis of clinical, paraclinical, laboratory and instrumental studies. The dietary supplement Optilact® was prescribed in order to relieve the main complaints — constipation, flatulence, to reduce pain symptoms and improve the general condition of the patient. The effectiveness of therapy was evaluated on the basis of the clinical dynamics of pain and dyspeptic complaints, reduction of constipation. The dyna­mics of coprological data was assessed by the end of the course of dietary supplement administration. Results. The findings indicate the feasibility and effectiveness of synbiotic Optilact® in children with irritable bowel syndrome (variant with constipation). The positive dynamics of pain and dyspeptic manifestations, the absence of side effects make it possible to use it in children. Conclusions. The use of the dietary supplement Optilact® in the comprehensive therapy of patients with IBS (variant with constipation) reduces pain and dyspeptic manifestations of the disease, eliminates constipation.


children; irritable bowel syndrome; treatment; dietary supplement Optilact®


Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016 May;150(6):1257-61. doi: 10.1053/j.gastro.2016.03.035.

Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional Disorders: Children and Adolescents. Gastroenterology. 2016 Feb 15. pii: S0016-5085(16)00181-5. doi: 10.1053/j.gastro.2016.02.015.

Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4. doi: 10.1016/j.cgh.2012.02.029.

Pechkurov DV, Allenova YuE, Tyazheva AA. Age-related specificities of functional disorders of the gastrointestinal tract manifested by abdominal pains from the positions of the biopsychosocial model. Pediatric Nutrition. 2015;13(2):11-16. (in Russian).

Trukhan DI, Viktorova IA, Bagisheva NV, Goloshubina VV. Irritable bowel syndrome: current issues in diagnosis and treatment. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh issledovanii. 2016;(11-1):89-93. (in Russian).

Minushkin ON, Topchii TB. Functional gastrointestinal disorders In Rome IV definition and some associated therapeutic approaches. Lechaschii Vrach. 2018;(5):84-88. (in Russian).

Bel’mer SV, Kovalenko AA, Gasilina TV, Akopian AN, Narinskaia NM. Irritated bowels syndrome: new horizons of drug therapy. Lechaschii Vrach. 2012;(2):68-72. (in Russian).

De Giorgio R, Barbara G. Is irritable bowel syndrome an inflammatory disorder? Curr Gastroenterol Rep. 2008 Aug;10(4):385-90.

Thabane M, Kottachchi DT, Marshall JK. Sistematic review and metaanalysis: the indicence and prognosis of postinfections irritable bovel syndrome. Aliment Pharmacol Ther. 2007 Aug 15;26(4):535-44. doi: 10.1111/j.1365-2036.2007.03399.x.

Kridler J, Kamat D. Irritable Bowel Syndrome: A Review for General Pediatricians. Pediatr Ann. 2016 Jan;45(1):e30-3. doi: 10.3928/00904481-20151208-01.

Rukunuzzaman M, Karim AB, Mazumder W, Nurullah M, Hussain F, Sultana K. Approach to a child with irritable bowel syndrome: a review. JNINB. 2016;2(1):34-39. doi: 10.3329/jninb.v2i1.32969.

Khavkin AI. Lactobacillus rhamnosus GG and intestinal microbiota. Pediatric Nutrition. 2018;16(2):42-51. doi: 10.20953/1727-5784-2018-2-42-51. (in Russian).

Ivashkin VT, Ivashkin KV. Human microbiome, applied to clinical practice. Rossijskij zurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(6):4-16. doi: 10.22416/1382-4376-2017-27-6-4-13. (in Russian).

Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002 Nov 15;35(10):1155-60. doi: 10.1086/342912.

Quigley EM. The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol. 2011 Feb;25(1):119-26. doi: 10.1016/j.bpg.2011.01.003.

Misra S, Sabui TK, Pal NK. A randomized controlled trial to evaluate the efficacy of Lactobacillus GG in infantile diarrhea. J Pediatr. 2009 Jul;155(1):129-32. doi: 10.1016/j.jpeds.2009.01.060.

Pechkurov DV, Turti TV, Belyaeva IA, Tjazheva AA. Intestinal microflora in children: from formation disturbances prophylaxis to preventing non-infectious diseases. Pediatricheskaya Farmakologiya. 2016;13(4):377-383. doi: 10.15690/pf.vl3i4/1611. (in Russian).

Copyright (c) 2019 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта